Pharco B International for Chemicals - PBIC

  • Home
  • Pharco B International for Chemicals - PBIC

Pharco B International for Chemicals - PBIC The site was commissioned in January 2015 and production started April, 2016.

PBIC was established in 2015 as a dedicated facility for the production of Active Pharmaceutical Ingredients (APIs) and associated chemicals such as intermediates.

Address

New Borg El Arab City, Second Industrial Zone No. 5, Block 22

Alerts

Be the first to know and let us send you an email when Pharco B International for Chemicals - PBIC posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Pharco B International for Chemicals - PBIC:

  • Want your practice to be the top-listed Clinic?

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

History

PBIC was established in 2015 as a dedicated facility for the production of Active Pharmaceutical Ingredients (APIs) and associated chemicals such as intermediates. The site was commissioned in January 2015 and production started in April 2016.

PBIC contracted with Tecnologia Sicurezza Ambiente (TSA) , Padova, Italy, to design and build this state-of-the-art facility. T.S.A. is an engineering firm specializing in the design of pharmaceutical, chemical and food facilities, water systems and waste treatment plants.

PBIC has a range of custom synthesis contracts with pharmaceutical companies including large tonnage production of APIs used in the treatment of HCV. PBIC collaborated with Chemelectiva , Novara, Italy in the development of the site’s first API – SOFOSBUVIR – a Hepatitis C Virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated in the treatment of chronic hepatitis C infection in combination with NS5A inhibitors. PBIC initiated collaboration with Chemelectiva , Novara, Italy for the development of RAVIDASVIR – a Hepatitis C Virus (HCV) NS5A inhibitor developed for the treatment of chronic Hepatitis C infection with Sofosbuvir.